Showing 41 - 60 results of 27,118 for search '(( 50 ((((mg decrease) OR (we decrease))) OR (a decrease)) ) OR ( e nn decrease ))', query time: 0.69s Refine Results
  1. 41
  2. 42

    DataSheet_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.docx by Zijing Ran (11429935)

    Published 2021
    “…Subjects included had all been treated with urate-lowering therapy (ULT) (febuxostat 20–80 mg/day or benzbromarone 25–50 mg/day, validated by the medical record). …”
  3. 43

    FTY720 treatment decreased tumor growth in a xenograft model of hepatoblastoma. by Laura L. Stafman (6577184)

    Published 2019
    “…When tumors reached an average of 150 mm<sup>3</sup>, mice were randomized to receive vehicle (ORA-Plus, 50 μL, n = 7) or FTY720 (10 mg/kg body weight/day in ORA-Plus, 50 μL, n = 7) by oral gavage for 16 days. …”
  4. 44

    Tacrolimus Decreases Albuminuria in Patients with IgA Nephropathy and Normal Blood Pressure: A Double-Blind Randomized Controlled Trial of Efficacy of Tacrolimus on IgA Nephropathy by Yong-Chul Kim (1637572)

    Published 2013
    “…We randomly assigned patients either to receive tacrolimus or placebo with stratification by using a renin angiotensin system blocker. …”
  5. 45
  6. 46
  7. 47
  8. 48
  9. 49
  10. 50
  11. 51
  12. 52
  13. 53
  14. 54
  15. 55
  16. 56
  17. 57

    Aged blood factors decrease cellular responses associated with delayed gingival wound repair by María Paz Saldías (4430032)

    Published 2017
    “…<div><p>Aging is a gradual biological process characterized by a decrease in cell and organism functions. …”
  18. 58
  19. 59
  20. 60

    A Novel Highly Potent Autotaxin/ENPP2 Inhibitor Produces Prolonged Decreases in Plasma Lysophosphatidic Acid Formation <i>In Vivo</i> and Regulates Urethral Tension by Hiroshi Saga (584103)

    Published 2014
    “…To date, several autotaxin/ENPP2 inhibitors have been reported; however, none were able to completely and continuously inhibit autotaxin/ENPP2 <i>in vivo</i>. In this study, we report the discovery of a highly potent autotaxin/ENPP2 inhibitor, ONO-8430506, which decreased plasma lysophosphatidic acid formation.…”